openPR Logo
Press release

Tyrosine Kinase Inhibitors - Pipeline Insights 2017

10-25-2017 01:28 PM CET | Health & Medicine

Press release from: Arizton Advisory & Intelligence

Tyrosine kinase Inhibitors-Pipeline Insights 2017

Tyrosine kinase Inhibitors-Pipeline Insights 2017

The “Tyrosine kinase Inhibitors-Pipeline Insights 2017″ report provides a comprehensive analysis of tyrosine kinase inhibitor drug candidates currently undergoing clinical trials. It covers detailed drug profiles of potential Akt inhibitors across various clinical development phases including–discovery, pre-clinical, IND, Phase I, Phase II, Phase III and pre-registration. The report also includes the pipeline products’ clinical trial data along with information on other development activities, including technology, licensing, collaborations, acquisitions, funding, patent, and USFDA and EMA designations. It also assesses the pipeline tyrosine kinase inhibitors by monotherapy, combination products, molecule type and route of administration. In addition to analysis on active pipeline molecules, the report also provides detailed information about discontinued and dormant drugs.

View Report:

The report profiles key players in developing potential tyrosine kinase drug candidates. The company profile section provides details such as company overview, business overview, financial overview, product portfolio, business strategies, and recent developments.

Few of the key marketed tyrosine kinase inhibitors include Dasatinib (Sprycel), Erlotinib (Tarceva), Gefitinib (Iressa), Imatinib (Gleevec). Lapatinib (Tykerb), Nilotinib (Tasigna), Sorafenib (Nexavar), Sunitinib (Sutent).

Over the past two decades, research studies have proved its efficacy for mitigation and control of non-cancerous diseases too. Thus research activity on use of inhibitors for various diseases such as Parkinson's disease and chronic obstructive pulmonary disorder is gradually increasing. The growing availability of these agents has enabled the pharmaceutical companies to develop new combination molecules which have the capacity to provide greater insight into the body’s acceptance of inhibitors so as to develop more effective therapies.

More recently, few molecules have been developed that inhibits tyrosine kinase these agents are in various stages of clinical development. The tyrosine kinase inhibitors pipeline has more than 15 molecules and is expected to achieve the regulatory approval in the near future, few of which are Oncoprex (CNVN202), ORS-1006, JNJ 49095397, RV-568, AP32788, APTO-500, and transtinib. In pipeline analysis, these are analyzed on the basis of route of administration (ROA) and type of molecule. The pipeline is also assessed based on monotherapy and combination therapy, and different clinical phases including Phase III, Phase II, Phase I and Pre-Clinical stage. Few of the companies which are involved in the development of tyrosine kinase inhibitor include IL-Yang Pharm, SRI, Sareum, Genprex, Arrien, J&J, and Takeda.

Reasons to Buy

To gain erudite insights about the Tyrosine Kinase inhibitor pipeline landscape

To ascertain unique product development dynamics and leverage it for new target identification, drug repositioning, and precision medicine

To optimize the pipeline product portfolio in correspondence with the dynamic pharmaceutical market

To identify competitors and design strategic initiatives for drug development activities

To understand the market and choose right partners for strategic collaborations

To obtain informed updates on drug termination/drug discontinuation

View Report:

Related Reports

1) Histone Deacetylase (HDAC) Inhibitors - Pipeline Insights 2017

2) Chimeric Antigen Receptor (CAR) T Cell Immunotherapy - Pipeline Insights 2017

About Arizton
Arizton – Advisory and Intelligence is an innovation and quality-driven firm, which offers cutting-edge research solutions to clients across the world. We excel in providing comprehensive market intelligence reports and advisory and consulting services.

Arizton has gained a paramount standpoint in the market research arena as it offers top of the line solutions to clients to assess market landscape and to finalize foolproof business strategies. We are committed to provide inclusive market research reports and consulting services to clients from diversified industries including –Consumer Goods & Retail Technology, Automotive and Mobility, Smart Tech, Healthcare and Lifesciences, Industrial Machinery, Chemicals and Materials, IT and Media, Logistics and Packaging

Arizton comprises a team of exuberant and well-experienced analysts who have mastered in generating incisive reports. Our specialist analysts possess exemplary skills in market research. We train our team in advanced research practices, techniques, and ethics to outperform in fabricating impregnable research reports.

Arizton Advisory & Intelligence
Chicago, Illinois, 60605
Call: +1-312-465-7864

This release was published on openPR.

Permanent link to this press release:

Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.

You can edit or delete your press release Tyrosine Kinase Inhibitors - Pipeline Insights 2017 here

News-ID: 785531 • Views: 325

More Releases from Arizton Advisory & Intelligence

E-Learning - Digitization and Modern Initiatives in COVID Situation - Arizton
The global e-learning market is expected to reach around $238 billion by 2024, growing at a CAGR of more than 8% during the forecast period. The continuous learning requirements for students and professionals, driven by sweeping trends over the past two decades due to globalization, talent migration, and consistent improvements in corporate competencies and individual talent grooming, have increased the scope of the e-learning market. Three major learning modes and avenues
Virtual Learning and Video Streaming Courses are Need of the Hour - Arizton
The global online program management market is expected to grow at a CAGR of over 14% during the forecast period 2019-2025. The OPM market exhibited steady growth over the last few years. With strengthening internet infrastructure, especially after 2010, the adoption of the internet in several areas has surged. The use of the internet in the education sector has led to a rise in several concepts such as e-learning, edutech, OPM,
The Demand for POS Terminals will Increase in the Healthcare Industry by 2025 | …
The global POS terminal market is expected to grow at a CAGR of over 8% during the period 2019-2025. Arizton estimates that the demand for POS terminals used in the healthcare industry is likely to witness a higher CAGR during the period 2020-2025 in terms of unit shipments. Since healthcare is a heavily regulated industry, additional care is required to protect patient information. To prevent a breach of security, the industry
Hand Sanitizers are Saving the World One Drop at a Time - Arizton
The global hand sanitizer market size is expected to generate revenues of around $3 billion by 2024, growing at an impressive CAGR of over 14% 2018-2024. The rising awareness toward personal hygiene and increased number of cases of virus outbreaks such as SARs and COVID19 recently, across various geographies has propelled the demand for hand hygiene solutions including hand sanitizers in the market. The market is witnessing increased demand from sectors

All 5 Releases

More Releases for Pipeline

Gastroenteritis Therapeutics Pipeline Analysis 2018
Gastroenteritis, also known as infectious diarrhoea, is an inflammatory disease caused by bacteria, viruses, or parasites through contaminated food and water. Download the sample report at: The disease can be symptomatized by vomiting, nausea, cramping, and diarrhoea. Dehydration, joint inflammation, conjunctivitis, salmonella infection, persistent diarrhoea syndrome, lactose intolerance, and irritable bowel syndrome are among the several complications associated with gastroenteritis. Get the detailed analysis at: The treatment medications for the disease
Hyperalgesia Therapeutics- Pipeline Analysis 2018
Hyperalgesia is a medical condition in which a person develops an increased sensitivity towards pain. There are several nerve pathways in the body where signals can start miscommunication with each other, resulting in hyperalgesia. Download the sample report @ Hyperalgesia can be categorized into several types which includes primary, secondary and opioid-induced hyperalgesia. The main symptom associated with the disease is increasing extreme reaction to painful stimuli without any new injury.
Autism-Pipeline Review H1 2018 has announced the addition of the “Global Autism Market Size Status and Forecast 2018”, The report classifies the global Autism Market in a precise manner to offer detailed insights about the aspects responsible for augmenting as well as restraining market growth. Pharmaceutical and Healthcare disease pipeline guide Autism-Pipeline Review, H1 2018, provides an overview of the Autism (Central Nervous System) pipeline landscape.Autism, also known as complex
Osteoarthritis-Pipeline Review H2 2017
Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Osteoarthritis-Pipeline Review, H2 2017, provides an overview of the Osteoarthritis (Musculoskeletal Disorders) pipeline landscape. Osteoarthritis (OA) is one of the most common forms of arthritis. It is a chronic condition in which the cartilage breaks down. Symptoms of osteoarthritis include sore or stiff joints, pain that is worse after activity, bone spurs and grating sensation. Risk factors include older age, joint
Hypotension (Cardiovascular) Pipeline Review H2, 2017 - Pharmaceutical Pipeline …
Market Research Hub's latest Pharmaceutical and Healthcare disease pipeline guide Hypotension Pipeline Review, H2 2017, provides an overview of the Hypotension (Cardiovascular) pipeline landscape. Low blood pressure, or hypotension, occurs when blood pressure during and after each heartbeat is much lower than usual. This means the heart, brain, and other parts of the body do not get enough blood. Symptoms include blurred vision, dizziness, confusion, sleeplessness and weakness. Treatment is
Insomnia (Central Nervous System) pipeline landscape - Pipeline Review, H1 2017
Latest Pharmaceutical and Healthcare disease pipeline guide “Insomnia Pipeline Review H1” 2017, provides an overview of the Insomnia (Central Nervous System) pipeline landscape. Insomnia is a sleep disorder that is characterized by difficulty falling and/or staying asleep. Symptoms include difficulty falling asleep at night, irritability, depression or anxiety, tension headaches and distress in the stomach and intestines. Risk factors include age, mental health disorder, stress and shift working. Report Highlights Global Markets Direct's